SLP Insider Trading

Insider Ownership Percentage: 19.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $6,083,852.50

Simulations Plus Insider Trading History Chart

This chart shows the insider buying and selling history at Simulations Plus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Simulations Plus Share Price & Price History

Current Price: $35.06
Price Change: Price Decrease of -0.15 (-0.43%)
As of 04/29/2025 05:00 PM ET

This chart shows the closing price history over time for SLP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$35.06Closing price on 04/29/25:

SEC Filings (Institutional Ownership Changes) for Simulations Plus (NASDAQ:SLP)

78.08% of Simulations Plus stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SLP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$18Mbought$1.25MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50M$0$50MTotal InflowsTotal Outflows
Simulations Plus logo
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Read More on Simulations Plus

Today's Range

Now: $35.06
Low: $34.45
High: $35.51

50 Day Range

MA: $28.48
Low: $23.82
High: $35.88

52 Week Range

Now: $35.06
Low: $23.01
High: $51.22

Volume

298,028 shs

Average Volume

200,693 shs

Market Capitalization

$705.09 million

P/E Ratio

87.65

Dividend Yield

N/A

Beta

1.13

Who are the company insiders with the largest holdings of Simulations Plus?

Simulations Plus' top insider shareholders include:
  1. Walter S Woltosz (Director)
  2. John Anthony Dibella II (Insider)
  3. Daniel L Weiner (Director)
  4. Lisa Lavange (Director)
  5. John Kenneth Paglia (Director)
Learn More about top insider investors at Simulations Plus.

Who are the major institutional investors of Simulations Plus?

Simulations Plus' top institutional investors include:
  1. Conestoga Capital Advisors LLC — 12.97%
  2. Kopion Asset Management LLC — 0.63%
  3. Bank of New York Mellon Corp — 0.59%
  4. Principal Financial Group Inc. — 0.46%
  5. Envestnet Asset Management Inc. — 0.41%
  6. Rhumbline Advisers — 0.33%
Learn More about top institutional investors of Simulations Plus stock.

Which major investors are selling Simulations Plus stock?

In the previous quarter, SLP stock was sold by these institutional investors:
  1. Kings Path Partners LLC
  2. InTrack Investment Management Inc
  3. SG Americas Securities LLC
  4. Hennion & Walsh Asset Management Inc.
  5. Bank of New York Mellon Corp
Within the last year, company insiders that have sold Simulations Plus company stock include:
  1. Walter S Woltosz (Director)
  2. John Anthony Dibella II (Insider)
  3. Daniel L Weiner (Director)
Learn More investors selling Simulations Plus stock.

Which major investors are buying Simulations Plus stock?

In the previous quarter, SLP stock was purchased by institutional investors including:
  1. Conestoga Capital Advisors LLC
  2. North Star Investment Management Corp.
  3. Envestnet Asset Management Inc.
  4. Azzad Asset Management Inc. ADV
  5. GAMMA Investing LLC
  6. Illumine Investment Management LLC
  7. Kopion Asset Management LLC
  8. Principal Financial Group Inc.